Eledon Pharmaceuticals, Inc. (ELDN) Q2 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Elladon Pharmaceuticals Second Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference call is recorded today, August 11, 2022. I now would like to turn the conference over to Paul Little, Chief Financial Officer of Elladon. Please go ahead, sir. Good afternoon, everyone. and thank you for joining Elladon's second quarter 2022 Operating and Financial Results Conference Call. I am joined on today's call by David Alexander Groh, Chief Executive Officer, and Jeff Forenstein, Chief Medical Officer. Steve Perrin, our President and Chief Scientific Officer, will not be joining today's call because he is attending a funeral. Earlier today, Elladon issued a press release announcing financial results for the second quarter ended June 30th, 2022. you may access the release under the Investors tab on our company's website at eladon.com. I would like to remind everyone that statements made during this conference call relating to Eladon's expected future performance, future business prospects, or future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from these forecasts due to the impact of many factors beyond the control of Eladon. Eladon expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events, or otherwise. Participants are directed to the risk factors set forth in Eladon's reports ...